Equities

Elite Pharmaceuticals Inc

ELTP:QBB

Elite Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.192
  • Today's Change0.000 / -0.05%
  • Shares traded263.00k
  • 1 Year change+414.75%
  • Beta0.0963
Data delayed at least 15 minutes, as of Jul 24 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. The Company specializes in developing and manufacturing oral, controlled-release drug products. It owns multiple generic products which has been licensed to Prasco, LLC and TAGI Pharma. The Company’s segments include Abbreviated New Drug Applications (ANDA) and New Drug Application (NDA). The Company’s products include Phentermine HCl 37.5mg tablets, Loxapine Succinate 5mg, 10mg, 25mg and 50gm capsules, Phentermine HCl 15mg and 30mg capsules, Naltrexone HCl 50mg tablets, Dantrolene Sodium Capsules 25mg, 50mg and 100mg, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg, 20mg and 30mg tablets, Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg capsules and others.

  • Revenue in USD (TTM)56.63m
  • Net income in USD20.11m
  • Incorporated2012
  • Employees64.00
  • Location
    Elite Pharmaceuticals Inc165 Ludlow AveNORTHVALE 07647-2305United StatesUSA
  • Phone+1 (201) 750-2646
  • Websitehttps://www.elitepharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hongchang International Co Ltd2.67m-365.80k129.71m8.00--3.28--48.64-0.0006-0.00060.00550.07630.0993--175.86---1.36-7.98-1.42-10.943.0311.47-13.72-64.885.86--0.2263--3,289.22---42.63------
Amylyx Pharmaceuticals Inc398.00m-71.10m133.29m384.00--0.4107--0.3349-1.07-1.075.744.770.96446.7421.001,036,461.00-17.23---20.84--88.93---17.86--4.48--0.00--1,612.94--124.84------
Biostem Technologies Inc58.01m159.39k136.36m67.00--20.69355.142.35-0.0865-0.08653.600.40642.385.172.78--0.6536--9.45--94.16--0.2748--1.101.230.3959--------------
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
OptiNose Inc74.02m-30.75m147.74m132.00------2.00-0.2733-0.27330.659-0.87770.74530.87644.74560,772.80-30.91-48.25---98.9588.9886.96-41.47-131.662.17-1.164.16---6.9358.6452.58---27.96--
Assertio Holdings Inc142.05m-332.97m154.10m53.00--1.15--1.08-3.95-3.951.661.410.40811.193.192,680,208.00-95.65-21.51-130.77-32.0576.9688.68-234.40-62.101.45--0.2231---2.67-13.38-402.80---28.25--
Lifecore Biomedical Inc103.27m-64.24m171.67m459.00------1.66-2.12-3.293.431.160.3911.963.07224,986.90-24.32-5.67-41.13-8.0727.1021.91-62.20-11.901.35-1.050.7495---7.19-27.74-315.07---8.55--
Scpharmaceuticals Inc17.63m-57.71m177.39m135.00--7.22--10.06-1.49-1.490.45450.68140.17130.75664.02130,607.40-56.07-38.23-62.13-42.3171.69---327.29-1,360.165.44-16.600.6159-------48.79------
Mediwound Ltd19.85m-12.75m182.42m100.00--8.04--9.19-1.38-1.382.152.440.3035.645.07198,510.00-19.46-24.48-25.65-32.9216.9243.27-64.24-38.431.83--0.218---29.4840.6065.73--64.66--
Elite Pharmaceuticals Inc56.63m20.11m195.52m64.009.763.569.103.450.01970.01970.05540.05390.90932.695.02884,767.8032.2919.0738.7924.2946.5546.6335.5120.772.081.700.13990.0065.7949.55464.56--111.50--
ASP Isotopes Inc1.27m-19.62m201.75m76.00--14.14--158.44-0.5335-0.53350.03440.21640.0425----16,755.00-65.49---81.59--32.81---1,542.66-----17.390.633-------229.34------
Inhibrx Biosciences Inc1.78m-271.16m206.28m166.00--60.65--115.69-5.35-5.350.03580.2350.0066--7.5110,740.96-99.40-77.06-123.13-93.91-----15,116.15-1,590.91---12.670.9474---17.88-26.85-66.20--26.30--
Greenwich Lifesciences Inc0.00-9.24m206.60m3.00--40.33-----0.719-0.7190.000.39770.00----0.00-106.03-36.43-109.97-38.31------------0.00-------13.63------
Zevra Therapeutics Inc28.01m-50.90m262.42m65.00--5.38--9.37-1.34-1.340.75131.170.2172--3.47430,876.90-39.48-32.11-47.94-39.8951.11---181.75-128.42----0.4683--170.26---72.00--69.75--
CorMedix Inc0.00-50.24m265.45m82.00--4.58-----0.9291-0.92910.001.060.00----0.00-78.96-54.84-88.88-62.32--6.18---18,323.426.41--0.00---100.00---56.02--46.27--
Procaps Group SA414.10m52.20m269.65m5.50k4.596.853.870.65120.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Data as of Jul 24 2024. Currency figures normalised to Elite Pharmaceuticals Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.